Charles River Laboratories
CRL
$185.39
+7.58%
Charles River Laboratories International, Inc. is a leading global provider of essential products and services to accelerate the drug discovery and development process, operating within the Medical - Diagnostics & Research industry. The company is a market leader and critical partner to pharmaceutical and biotechnology firms, distinguished by its comprehensive portfolio spanning research models, discovery and safety assessment services, and manufacturing support. The current investor narrative is dominated by a debate over the company's near-term growth trajectory and margin profile, as recent quarterly results show a slight year-over-year revenue decline and a significant net loss, raising questions about the sustainability of its core contract research organization (CRO) demand amidst a challenging biotech funding environment.…
CRL
Charles River Laboratories
$185.39
CRL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Charles River Laboratories's 12-month outlook, with a consensus price target around $241.01 and implied upside of +30.0% versus the current price.
Average Target
$241.01
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$148 - $241
Analyst target range
Analyst coverage for CRL is active, with 8 analysts providing estimates. The consensus sentiment appears mixed but leans cautiously optimistic, as evidenced by recent institutional actions including 'Buy' ratings from TD Cowen and Citigroup and 'Overweight' from Barclays, balanced by several 'Neutral' ratings from firms like UBS and Mizuho. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS forecast of $15.39 for the coming period on revenue of approximately $4.30 billion, indicating expectations for a strong earnings recovery. Without a specific average price target, the implied upside cannot be calculated, but the forward PE of 13.43 based on these estimates suggests the market has not priced in excessive optimism. The target range is wide, with estimated EPS spanning from a low of $14.77 to a high of $16.12, reflecting uncertainty around the pace and magnitude of the expected profit rebound. The recent pattern of reiterated ratings without major downgrades following the poor Q4 results suggests analysts are largely maintaining their long-term theses, viewing the weakness as potentially transient rather than structural.
Bulls vs Bears: CRL Investment Factors
The investment debate for CRL is a classic clash between valuation and momentum. The bear case, currently supported by stronger near-term evidence, is driven by a severe, unexpected collapse in Q4 profitability and a concerning reversal in revenue growth, exacerbated by extreme stock volatility and negative price momentum. The bull case rests on the expectation that these issues are transient, pointing to the company's robust free cash flow, its essential market position, and a forward valuation that prices in a sharp earnings recovery. The single most important tension is the timing and certainty of this expected profit rebound. If CRL can demonstrate a return to sequential revenue growth and positive net income in the next quarter, the bullish valuation argument will gain substantial credibility. If the Q4 loss proves indicative of deeper structural or demand issues, the stock's high beta and technical breakdown could lead to a re-test of its 52-week low.
Bullish
- Strong Free Cash Flow Generation: Despite recent net losses, the company generated $518.5 million in trailing twelve-month free cash flow. This robust cash generation provides a significant buffer, funding operations and debt service without reliance on external capital, which is a critical strength in a challenging funding environment.
- Attractive Valuation on Sales and Forward Earnings: The stock trades at a trailing PS ratio of 2.51 and an EV/Sales of 2.66, which is near the lower end of its historical spectrum. More importantly, the forward P/E of 13.43, based on an average EPS estimate of $15.39, suggests the market expects a sharp earnings recovery, offering a potential valuation gap.
- Analyst Confidence in Long-Term Recovery: Analyst sentiment remains cautiously optimistic with 8 firms covering the stock, including recent 'Buy' and 'Overweight' ratings from TD Cowen, Citigroup, and Barclays. The average EPS forecast of $15.39 for the coming period signals a strong expected rebound from the recent quarterly loss of -$5.62 per share.
- Market Leadership in Essential Services: As a leading global provider of preclinical research services and models, CRL holds a critical, entrenched position in the drug development pipeline. This essential role provides a degree of demand resilience, even during periods of biotech funding pressure, supporting a long-term growth thesis.
Bearish
- Severe Profitability Collapse in Q4: The company reported a massive Q4 net loss of -$276.6 million, translating to a net margin of -27.8% and an EPS of -$5.62. This represents a stark reversal from profitability in the prior three quarters and raises serious questions about operational stability and cost control.
- Revenue Decline and Growth Stagnation: Q4 2025 revenue of $994.2 million declined 0.83% year-over-year, continuing a sequential downtrend from Q3's $1.00B and Q2's $1.03B. This multi-quarter deceleration to negative growth indicates broad-based softness in core CRO demand, likely tied to the challenging biotech funding environment.
- Extreme Stock Volatility and Underperformance: The stock has a beta of 1.616, making it 62% more volatile than the market, and has suffered a 21.24% decline over the past three months. It has severely underperformed the S&P 500 by -15.19% over the past month, reflecting a loss of investor confidence and heightened downside risk.
- High Short Interest and Negative Momentum: A short ratio of 5.43 indicates significant bearish sentiment in the market. The technical downtrend is pronounced, with the stock down 7.94% over six months and experiencing a maximum drawdown of -36.89%, signaling persistent selling pressure and a broken price trend.
CRL Technical Analysis
The stock is in a pronounced downtrend from its recent highs, having declined 21.24% over the past three months and 7.94% over the past six months. Currently trading at $165.78, the price sits at approximately 72% of its 52-week range ($113.89 to $228.88), indicating it has retreated significantly from its highs and is now in the lower-middle portion of its annual band, suggesting a potential value zone but also reflecting persistent selling pressure. Recent short-term momentum is decisively negative, with the stock down 5.21% over the past month, which contrasts sharply with the S&P 500's gain of 9.98%, resulting in a severe relative strength deficit of -15.19%. This divergence from the broader market and the longer-term 1-year gain of 41.83% signals a significant loss of momentum and potential trend reversal, likely driven by disappointing fundamental results. Key technical support is anchored at the 52-week low of $113.89, while immediate resistance lies near the recent breakdown levels around $180-$185. A beta of 1.616 indicates the stock is approximately 62% more volatile than the broader market, which amplifies both downside risk and potential upside during recoveries, a critical factor for risk-aware investors given the stock's recent 36.89% maximum drawdown.
Beta
1.45
1.45x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$114-$229
Price range past year
Annual Return
+55.2%
Cumulative gain past year
| Period | CRL Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | +10.4% |
| 3m | -8.0% | +5.5% |
| 6m | +8.5% | +8.0% |
| 1y | +55.2% | +28.4% |
| ytd | -8.4% | +6.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRL Fundamental Analysis
Revenue growth has stalled and turned negative, with the most recent Q4 2025 revenue of $994.2 million representing a year-over-year decline of 0.83%. This follows a sequential pattern from Q3's $1.00 billion and Q2's $1.03 billion, indicating a multi-quarter trend of decelerating to negative growth. The segment data shows Discovery and Safety Assessment as the largest contributor at $591.6 million, but the overall trend suggests broad-based softness in demand for preclinical services. Profitability has deteriorated sharply, with the company reporting a substantial net loss of -$276.6 million in Q4, translating to a net margin of -27.8%, a stark reversal from the profitability in the preceding three quarters (Q3 net income of $54.4 million, Q2 $52.3 million, Q1 $25.5 million). The gross margin of 30.96% in Q4, while down from the 33.7% in Q3, remains within a band typical for the CRO industry, but the operating margin of 12.1% was pressured by significant other expenses. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.97, and the current ratio of 1.29 indicates adequate short-term liquidity. Crucially, the company generated robust trailing twelve-month free cash flow of $518.5 million, providing a strong internal funding source for operations and debt service, which mitigates some of the near-term profitability concerns.
Quarterly Revenue
$994227000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.30%
Latest Quarter
Free Cash Flow
$518494000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRL Overvalued?
Given the negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 2.51 and an Enterprise Value-to-Sales (EV/Sales) of 2.66. The forward PE ratio of 13.43, based on positive estimated earnings, suggests the market expects a return to profitability, creating a significant valuation gap between the negative trailing PE of -69.93 and the forward-looking multiple. Compared to industry averages, the PS ratio of 2.51 appears reasonable for a leading CRO, though a direct industry average PS is not provided in the data; the valuation must be assessed relative to the company's own history and growth prospects. Historically, the stock's own PS ratio has fluctuated significantly, reaching as high as 10.08 in Q4 2025 and averaging much higher levels over the past several years. The current PS of 2.51 is near the lower end of its historical spectrum, suggesting the market is pricing in a scenario of fundamental deterioration or stagnant growth, presenting a potential value opportunity if the company can stabilize its operations and return to its historical growth and margin profile.
PE
-69.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -11x~77x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the alarming deterioration in profitability and uncertain growth trajectory. The Q4 net loss of -$276.6M and a trailing net margin of -3.6% reveal significant earnings volatility, raising the risk that the company's valuation, which relies on a forward P/E of 13.43, is predicated on an uncertain recovery. While strong TTM FCF of $518.5M and a current ratio of 1.29 provide liquidity, a debt-to-equity of 0.97 means balance sheet flexibility could be constrained if losses persist. The core risk is that the recent revenue decline of -0.83% YoY is not a temporary blip but a sign of sustained demand weakness in its preclinical CRO services, invalidating growth assumptions.
Market & Competitive Risks are heightened by the stock's premium volatility and compressed valuation. With a beta of 1.616, CRL is highly sensitive to market swings, and its severe underperformance versus the S&P 500 (-15.19% over 1 month) indicates it is being punished as a 'show-me' story. The current PS ratio of 2.51, while low historically, could face further compression if the sector de-rates or if competitors gain share during this period of soft demand. The company is exposed to the biotech funding cycle; prolonged high interest rates could continue to pressure client R&D budgets, delaying a recovery in order flow and service utilization.
Worst-Case Scenario involves a failure to arrest the negative operational momentum. If the next quarter confirms the revenue decline is accelerating and losses widen, analyst estimates would be slashed, destroying the forward earnings narrative. This could trigger a wave of downgrades and force a re-rating to a distressed sales multiple. In this adverse scenario, the stock could realistically fall to re-test its 52-week low of $113.89, representing a downside of approximately -31% from the current price of $165.78. The high short interest and 36.89% historical max drawdown demonstrate the stock's capacity for such a severe decline if sentiment turns decisively negative.